Lower thirds:

00:02 Report by Manira Chaudhary and Shailesh Kumar
00:35 Suhridh Sundaram | Co-founder, Avay Biosciences
00:48 Manish Amin | Avay Biosciences
01:27 Suhridh Sundaram | Co-founder, Avay Biosciences
02:22 Manish Amin | Avay Biosciences

The machine you see on the screen is a 3D bioprinter- a device scripting an important chapter in India’s biotech journey.

Avay Biosciences, started by Manish Amin and Suhridh Sundaram in 2021,is one of the few in India that manufactures 3D bioprinters- specialized machines that can help create tissues or cells, that mimic human organs. 

The technology is transformative—used in medical research, drug testing, and potentially, one day, to build fully functional organs like the heart or lungs.

SOT: Suhridh Sundaram: 

“The ultimate vision is to be able to actually provide, you know, organs to people. And I think that's something that the world wants today. Everyone who is suffering from some sort of ailment would like a solution to that.”

SOT: Manish Amin: 

“If there is anything close to replicating an organ or cloning an organ, it is this technology.  There is nothing which is close to it." 

When the launched Avay in 2021, the potential of the industry was evident. The estimates vary from report to report- but all point to a substantial growth in the industry-reaching a figure of 5-7 billion USD by 2032.
(https://www.persistencemarketresearch.com/market-research/3d-bioprinting-market.asp)

Avay has since expanded- building machines, creating its own biomaterials, and even printing liver cells to study how drugs interact with the organ.

SOT: Suhridh Sundaram, Co-founder, Avay Biosciences: 

“We are targeting specifically preclinical drug testing, which is before we get to humans, that is the clinical aspect of things, what we do in the lab to validate that a drug would  actually work on a human being. That is the space we are in. The preclinical drug testing market globally is around 30 billion. In India, it is roughly about 5 to 10 percent of that, so we are looking at easily 2 to 3 billion dollars.”

The team is now working on two key goals—Growing cancer tumors in vitro to test drugs, and reducing animal testing in drug and cosmetic research through 3D-printed alternatives.

Both use cases have strong global demand- and the founders are confident of their numbers.

SOT: Manish Amin, Avay Biosciences:

“We have seen a 60% year on year growth since 2023. Going forward, we are looking at multiples of 120% growth from next year because we are expanding to different industries. If I talk about 2030, we are looking at around 5 million dollar revenues. That’s our target”

These numbers reflect more than just business success-they signal growing faith in the future of biotech and 3D bioprinting in India, as the industry slowly begins to realize its full potential.

END